Page last updated: 2024-12-08

zalospirone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zalospirone: a partial 5-HT1A receptor agonist; RN given refers to (3aalpha,4alpha,4abeta,6abeta,7alpha,7aalpha)-isomer; RN for cpd without isomeric designation not available 4/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163925
CHEMBL ID3990567
SCHEMBL ID247563
MeSH IDM0185554

Synonyms (21)

Synonym
114298-18-9
gtpl58
wy-47,846
(1r,2r,6s,7s,8s,11r)-4-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-4-azatetracyclo[5.4.2.0^{2,6}.0^{8,11}]trideca-9,12-diene-3,5-dione
wy-47846
zalospirone
zalospirona [inn-spanish]
zalospirona
unii-0449o95z1j
zalospirone [inn]
zalospironum [inn-latin]
zalospironum
0449o95z1j ,
4,7-etheno-1h-cyclobut(f)isoindole-1,3(2h)-dione, 3a,4,4a,6a,7,7a-hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, (3aalpha,4alpha,4abeta,6abeta,7alpha,7aalpha)-
4,7-etheno-1h-cyclobut(f)isoindole-1,3(2h)-dione, 3a,4,4a,6a,7,7a-hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, (3a.alpha.,4.beta.,4a.alpha.,6a.alpha,7.beta.,7a.alpha.)-
(1r*,2r*,5s*,6s*,7s*,8r*)-n-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)tricyclo(4.2.2.0(sup 2,5))deca-3,9-diene-7,8-dicarboximide
SCHEMBL247563
CHEMBL3990567
Q12747409
(1s,2s,6r,7r,8r,11s)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatetracyclo[5.4.2.02,6.08,11]trideca-9,12-diene-3,5-dione
DTXSID501028422

Research Excerpts

Actions

ExcerptReferenceRelevance
"Zalospirone did not produce the syndrome but it antagonized the syndrome produced by 8-OH-DPAT."( Antidepressant-like activity of compounds with varying efficacy at 5-HT1A receptors.
Lucki, I; Singh, A, 1993
)
1.01

Dosage Studied

ExcerptRelevanceReference
" Improvement with the 6-mg or 15-mg doses was greater than that with placebo, but not significantly so, suggesting a dose-response effect."( Zalospirone in major depression: a placebo-controlled multicenter study.
Derivan, A; Kunz, N; Pallay, A; Rickels, K; Schweizer, E, 1996
)
1.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]